Moleculin Biotech Investor Relations Material
Latest events
Study Update
Moleculin Biotech
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Moleculin Biotech Inc
Access all reports
Moleculin Biotech, Inc. (MBRX) is a clinical-stage pharmaceutical company aiming to develop treatments addressing some of the most challenging diseases in the world, including highly resistant cancers and viruses. The company's lead drug, Annamycin, is a next-generation anthracycline designed to overcome multidrug resistance with minimal cardiotoxicity, currently under development for relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma (STS) lung metastases. Additionally, Moleculin is working on WP1066, an Immune/Transcription Modulator targeting brain tumors, pancreatic cancer, and other malignancies, alongside WP1220 for cutaneous T-cell lymphoma and WP1122, aimed at treating COVID-19 and glioblastoma multiforme, among other conditions. The company is headquartered in Houston, Texas, and its shares are listed on the Nasdaq.
Latest articles
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
)
D. E. Shaw & Co: Inside the Quiet Giant of Quant Finance
A deep dive into D. E. Shaw's evolution from a $28M quant startup to a $65B hedge fund giant, built on research, computing, and quiet consistency.
2 Jul 2025
)
Pershing Square Capital Management: Conviction, Reinvention, and Contrarian Investing
Pershing Square Capital Management has grown into a top-tier hedge fund through reinvention, conviction, and focus on long-term value creation.
2 Jul 2025
Ticker symbol
MBRX
Country
🇺🇸 United States